Доступ предоставлен для: Guest
Journal of Environmental Pathology, Toxicology and Oncology
Главный редактор: Qian Peng (open in a new tab)

Выходит 4 номеров в год

ISSN Печать: 0731-8898

ISSN Онлайн: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Human Immunodeficiency Virus Type 1 Pharmacogenomics in Clinical Practice: Relevance of HIV-1 Drug Resistance Testing (Part 2)

Том 22, Выпуск 4, 2003, 46 pages
DOI: 10.1615/JEnvPathToxOncol.v22.i4.10
Get accessGet access

Краткое описание

Throughout most of the past century, physicians could offer patients no treatments for infections caused by viruses. The experience with treatment of infection by human immunodeficiency virus (HIV) has changed the way healthcare workers deal with viral infections and has triggered a growing rate of discovery and use of antiviral agents, the first fruits of the expanding genomics revolution. HIV treatment also provides an informative paradigm for pharmacogenomics because control of infection and its consequences is limited by the development of viral drug resistance and by host factors. This report summarizes studies published to date on the significance of testing of HIV-1 resistance to antiretroviral drugs. The only Food and Drug Administration-approved kit is commercially available through Visible Genetics, Inc., for HIV drug resistance testing by genotypic sequencing. Genotyping sequencing alone is most likely an adequate test to assist in the therapeutic decision-making process in cases of previous regimen failure, treatment-naive patients in areas of high prevalence of transmitted resistant virus, and pregnant women. However, in exceptional cases of highly complex mutation patterns and extensive cross-resistance, it may be useful to obtain a phenotype test, because that result may more easily identify drugs to which the virus is least resistant. There are no published clinical trial results on the usefulness of the so-called virtual phenotype over genotypic sequencing alone. The paradigm of viral pharmacogenomics in the form of HIV genotypic sequencing has been not only useful to the treatment of other viral diseases but also important to the real-life implementation of the growing discipline of genomics or molecular medicine. The application of this paradigm to the thousands of potential therapeutic targets that have become available through the various human genome projects will certainly gradually change the landscape of diagnosis and management of many diseases, including cancer.

ЦИТИРОВАНО В
  1. Stebbing Justin, Bower Mark, Comparative pharmacogenomics of antiretroviral and cytotoxic treatments, The Lancet Oncology, 7, 1, 2006. Crossref

  2. Klimas Nancy, Koneru Anne O’Brien, Fletcher Mary Ann, Overview of HIV, Psychosomatic Medicine, 70, 5, 2008. Crossref

  3. Zaki Eitezaz A., El-Daly Mai M., Abdulhaq Ahmed, Al-Subhi Tagreed L., Hassan Ahmed M., El-Kafrawy Sherif A., Alhazmi Mohammad M., Darraj Majid A., Azhar Esam I., Genotyping and antiretroviral drug resistance of human immunodeficiency Virus-1 in Jazan, Saudi Arabia, Medicine, 99, 49, 2020. Crossref

1367 Просмотры статей 4 Загрузка статей Метрики
1367 ПРОСМОТРЫ 4 ЗАГРУЗКИ 3 Crossref ЦИТАТЫ Google
Scholar
ЦИТАТЫ

Статьи с похожим содержанием:

Human Immunodeficiency Virus Type 1 Pharmacogenomics in Clinical Practice: Relevance of HIV-1 Drug Resistance Testing (Part 1) Journal of Environmental Pathology, Toxicology and Oncology, Vol.22, 2003, issue 3
Nancy G. Klimas, Margaret Marchette, Charles Mitchell, Eduardo Meneses Sierra, Alejandro Isava, Dushyantha Jayaweera, Enriqueta Nunez, J. Brian Page, Gwendolyn Scott, Roberto Patarca, Nelson J. Rodriguez, Mary Ann Fletcher, Delia Rivera, Michael Kolber, Mirtha M. Sanabia, Rafael Campo, Cindy W. Mask, Jose Moreno, Michael Alter, Ricardo Vallejo, Catherine Boulanger
Drug Development for Metastasis Prevention Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Steven M. Dubinett, Yari Fontebasso
Human Papilloma Virus−Associated Oral Pharyngeal Squamous Cell Carcinoma: Prevalence, Prevention, and Awareness of Vaccination in the Indian Population Critical Reviews™ in Oncogenesis, Vol.28, 2023, issue 2
Ragini D. Singh, Naveen Chaudhary, Smitha Mathews, Vigi Chaudhary
Diagnostic Modalities for the Detection of SARS-CoV-2: Principles, Advantages, and Pitfalls Critical Reviews™ in Biomedical Engineering, Vol.48, 2020, issue 4
Suresh Anand BS, Ilamaran M, Jonath Sujan, Ashwin Kumar N
Gonorrhea: Immune Escape and Immunotherapeutic Strategies Onco Therapeutics, Vol.7, 2016, issue 3-4
Ailina Heng Lao, Benjamin Bonavida
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции Цены и условия подписки Begell House Контакты Language English 中文 Русский Português German French Spain